DNDi aims to:

  • Help end the neglect of paediatric HIV by developing optimal child-friendly antiretroviral formulations for children living with HIV, with a special focus on infants and young children who are at the highest risk of dying without treatment.

 

The current paediatric HIV portfolio includes:

Development

Development

4-in-1 ABC/3TC/LPV/r

Implementation

Implementation

Super-booster therapy for children with HIV/TB
2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC

 

For more details on each project, see DNDi‘s Global Portfolio